PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Naldemedine - Constipation

PAD Profile : Naldemedine - Constipation Important

Keywords :
opioid induced constipation
Brand Names Include :
Rizmoic
Important Information :
Opioid-induced constipation. Only after other laxatives have been unsuccessful.

Traffic Light Status

Status 1 of 1.

Status :
Green
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
R
NICE
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
03 July 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands APC have adopted the CKS principles for the management of constipation in adults.

Management | Constipation | CKS | NICE

The CKS guidance covers the management of constipation in adults (including pregnant women and those who are breastfeeding), for short-duration and chronic constipation, and faecal loading and/or impaction.

Refer to the formulary for Traffic Light status / place in therapy of locally agreed treatment options.

02 December 2020
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands ICS Area Prescribing Committee approves naldemedine as another treatment option for Opioid  Induced Constipation (OIC) in line with NICE TA651.

Naldemedine will be given a GREEN traffic light status for this indication.

Associated BNF Codes

01. Gastro-Intestinal System
01.06.06. Peripheral opioid-receptor antagonists
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More